SYNB1020

Generic Name
SYNB1020
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
-
Background

SYNB1020 is an engineered strain of Escherichia coli Nissle 1917 developed by Synlogic Inc. It was initially designed to convert ammonia to L-arginine and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016; however, the manufacturer discontinued further development of SYNB1020 to treat hyperammonemia due to a lack...

Associated Conditions
-
Associated Therapies
-

Safety, Tolerability and Pharmacodynamics of SYNB1020

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2018-02-27
Last Posted Date
2021-05-13
Lead Sponsor
Synlogic
Target Recruit Count
23
Registration Number
NCT03447730
Locations
🇺🇸

Southern California Research Center, Coronado, California, United States

🇺🇸

Inland Empire Liver Foundation, Rialto, California, United States

🇺🇸

Texas Liver Institute, San Antonio, Texas, United States

and more 2 locations

Safety and Tolerability of SYNB1020-CP-001

First Posted Date
2017-06-07
Last Posted Date
2021-05-12
Lead Sponsor
Synlogic
Target Recruit Count
52
Registration Number
NCT03179878
Locations
🇺🇸

Parexel, Brooklyn, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath